Prognostic factor and treatment strategy for clinical N1 non-small cell lung cancer

被引:6
|
作者
Tamura, Masaya [1 ]
Matsumoto, Isao [1 ]
Tanaka, Yusuke [1 ]
Saito, Daisuke [1 ]
Yoshida, Shuhei [1 ]
Takata, Munehisa [1 ]
Takemura, Hirofumi [1 ]
机构
[1] Kanazawa Univ, Dept Thorac Cardiovasc & Gen Surg, Takara Machi 13-1, Kanazawa, Ishikawa 9208640, Japan
关键词
NSCLC; Clinical N1; Prognostic factor; LYMPH-NODES; CARCINOMA; DIAGNOSIS;
D O I
10.1007/s11748-019-01205-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The aim of this study is to evaluate the surgical results of clinical N1 disease and to clarify the high-risk clinical N1 subgroup. Methods Between 1990 and 2012, 137 patients who were clinically diagnosed as having N1 disease were enrolled. Their medical records were reviewed to assess clinical characteristics, radiologic findings, pathologic results, postoperative outcomes, recurrence patterns, and survival. Logistic regression analysis was used to identify independent predictive factors for pathologic N2 upstaging. To determine which factors were significantly associated with survival, a multivariate analysis using a Cox proportional hazards model was performed. Results More cases were pathological N2 in adenocarcinoma than squamous cell carcinoma (p = 0.039). The overall survival rates at 5 years were 54.9%, 36.7% in group upper lobe, middle and lower lobe, respectively (p = 0.013). Logistic regression analyses revealed that #10 positive (p = 0.002, HR 4.625) and adenocarcinoma (p = 0.029, HR 1.544) were significant predictor of pathologic N2 disease. Multivariate analyses revealed that pathologic N2 (p = 0.007, HR 4.186), middle and lower lobe (p = 0.009, HR 2.045) and presence of #10 (p = 0.024, HR 1.871) were independent prognostic factors. Patients with upper lobe and absence of #10 showed a significantly higher 5-year survival rate than patients with middle and lower lobe and presence of #10 (62.1 vs 25.9%: p < 0.0001). Conclusions Among patients with cN1, pathological N2 disease, tumor in middle and lower lobe and clinical #10 lymph node positive were high-risk subgroup. Further analyses using larger numbers of patients with N1 disease from multiple centers are necessary.
引用
收藏
页码:261 / 265
页数:5
相关论文
共 50 条
  • [1] Prognostic factor and treatment strategy for clinical N1 non-small cell lung cancer
    Masaya Tamura
    Isao Matsumoto
    Yusuke Tanaka
    Daisuke Saito
    Shuhei Yoshida
    Munehisa Takata
    Hirofumi Takemura
    [J]. General Thoracic and Cardiovascular Surgery, 2020, 68 : 261 - 265
  • [2] Outcome of Surgical Treatment for Clinical N1 Non-Small Cell Lung Cancer
    Nemoto, D.
    Ito, H.
    Tsuboi, T.
    Eriguchi, D.
    Samejima, J.
    Nagashima, T.
    Nakayama, H.
    Masuda, M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S909 - S909
  • [3] Heterogeneity of Clinical N1 Non-Small Cell Lung Cancer
    Kim, Dohun
    Choi, Yong Soo
    Kim, Hong Kwan
    Kim, Kwhanmien
    Kim, Jhingook
    Shim, Young Mog
    [J]. THORACIC AND CARDIOVASCULAR SURGEON, 2014, 62 (02): : 103 - 108
  • [4] The Number of Lymph Node Metastases as a Prognostic Factor in Patients With N1 Non-small Cell Lung Cancer
    Jonnalagadda, Sirisha
    Smith, Cardinale
    Mhango, Grace
    Wisnivesky, Juan P.
    [J]. CHEST, 2011, 140 (02) : 433 - 440
  • [5] The Number Of Lymph Node Metastases As A Prognostic Factor In Patients With N1 Non-Small Cell Lung Cancer
    Jonnalagadda, S.
    Smith, C. B.
    Mhango, G.
    Wisnivesky, J. P.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [6] Definitive Hypofractionated Radiation in the Treatment of Clinical N1 Non-Small Cell Lung Cancer (NSCLC)
    Gits, Colton C.
    Rehman, Sana
    Roach, Michael C.
    Speirs, Christina K.
    Chundury, Anupama
    Henke, Lauren
    Mullen, Daniel
    DeWees, Todd
    Bradley, Jeffrey D.
    Robinson, Clifford G.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (02): : E37 - E37
  • [7] Mediastinal staging by videomediastinoscopy in clinical N1 non-small cell lung cancer
    Bostantzoglou, Clementine
    Iliopoulou, Marianthi
    Hardavella, Georgia
    [J]. BREATHE, 2018, 14 (04) : 342 - 344
  • [8] Prognostic biomarker study in pathologically staged N1 non-small cell lung cancer
    Komaki, R
    Milas, L
    Ro, JY
    Fujii, T
    Perkins, P
    Allen, P
    Sikes, CR
    Mountain, CF
    Ordonez, NG
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 40 (04): : 787 - 796
  • [9] Prognostic factors after surgical resection of N1 non-small cell lung cancer
    Mordant, P.
    Pricopi, C.
    Legras, A.
    Arame, A.
    Foucault, C.
    Dujon, A.
    Le Pimpec-Barthes, F.
    Riquet, M.
    [J]. EJSO, 2015, 41 (05): : 696 - 701
  • [10] Survival and Prognostic Factor in Pathological N1 Non-Small-Cell Lung Cancer
    Yamamoto, Taketsugu
    Maehara, Takamitsu
    Masuda, Munetaka
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S670 - S670